Patents by Inventor Sean J. Morrison
Sean J. Morrison has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10227567Abstract: A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. This discovery is the basis for solid tumor stem cell compositions, methods for distinguishing functionally different populations of tumor cells, methods for using these tumor cell populations for studying the effects of therapeutic agents on tumor growth, and methods for identifying and testing novel anti-cancer therapies directed to solid tumor stem cells.Type: GrantFiled: September 7, 2016Date of Patent: March 12, 2019Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Michael F. Clarke, Sean J. Morrison, Max S. Wicha, Muhammad Al-Hajj
-
Publication number: 20170191032Abstract: The disclosure reports on the identification and isolation of adult mouse lateral ventricle subventricular zone (SVZ) neurosphere initiating cells (NICs) by flow cytometry on the basis of GlastmidEGFRhighPlexinB2highCD24?/lowO4/PSA-NCAM?/lowTer-119/CD45? markers (GEPCOT cells). These cells are highly mitotic and short-lived in vivo based on fate-mapping with Ascl1CreERT2 and Dlx1CreERT2. In contrast, pre-GEPCOT cells were quiescent, expressed higher Glast, and lower EGFR and PlexinB2. Pre-GEP-COT cells could not form neurospheres but expressed the stem cell markers Glast-CreERT, GFAP-CreERT2, Sox2CreERT2, and Gli1C-reERT2 and were long-lived in vivo. While GEPCOT NICs were ablated by temozolomide, pre-GEPCOT cells survived and repopulated the SVZ. Conditional deletion of the Bmi-1 polycomb protein depleted pre-GEPCOT and GEPCOT cells, though pre-GEPCOT cells were more dependent upon Bmi-1 for p16Ink4a repression.Type: ApplicationFiled: April 27, 2015Publication date: July 6, 2017Inventors: Sean J. MORRISON, John K. MICH
-
Publication number: 20170175083Abstract: A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. This discovery is the basis for solid tumor stem cell compositions, methods for distinguishing functionally different populations of tumor cells, methods for using these tumor cell populations for studying the effects of therapeutic agents on tumor growth, and methods for identifying and testing novel anti-cancer therapies directed to solid tumor stem cells.Type: ApplicationFiled: September 7, 2016Publication date: June 22, 2017Inventors: Michael F. Clarke, Sean J. Morrison, Max S. Wicha, Muhammad Al-Hajj
-
Publication number: 20170112865Abstract: The present invention relates to combination therapies for melanoma, and in particular, metastatic melanoma. Drugs for use in such combination in include MEK inhibitors, BRAF inhibitors and cardiac glycosides.Type: ApplicationFiled: April 28, 2015Publication date: April 27, 2017Inventors: Sean J. MORRISON, Ugur ESKIOCAK
-
Patent number: 9492538Abstract: A small percentage of cells within an established tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. The solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. This discovery is the basis for solid tumor stem cell compositions, methods for distinguishing functionally different populations of tumor cells, methods for using these tumor cell populations for studying the effects of therapeutic agents on tumor growth, and methods for identifying and testing novel anti-cancer therapies directed to solid tumor stem cells.Type: GrantFiled: June 10, 2005Date of Patent: November 15, 2016Assignee: The Regents of the University of MichiganInventors: Michael F. Clarke, Sean J. Morrison, Max S. Wicha, Muhammad Al-Hajj
-
Publication number: 20140011274Abstract: A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise to both more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. We have developed a xenograft model in which we have been able to establish tumors from primary tumors via injection of tumors in the mammary gland of severely immunodeficient mice. These xenograft assay have allowed us to do biological and molecular assays to characterize clonogenic solid tumor stem cells. We have also developed evidence that strongly implicates the Notch pathway, especially Notch 4, as playing a central pathway in carcinogenesis.Type: ApplicationFiled: December 14, 2012Publication date: January 9, 2014Applicant: The Regents of the University of MichiganInventors: Michael F. Clarke, Sean J. Morrison, Max S. Wicha, Muhammad Al-Hajj
-
Patent number: 8357491Abstract: A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise to both more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. We have developed a xenograft model in which we have been able to establish tumors from primary tumors via injection of tumors in the mammary gland of severely immunodeficient mice. These xenograft assay have allowed us to do biological and molecular assays to characterize clonogenic solid tumor stem cells. We have also developed evidence that strongly implicates the Notch pathway, especially Notch 4, as playing a central pathway in carcinogenesis.Type: GrantFiled: December 28, 2010Date of Patent: January 22, 2013Assignee: The Regents of the University of MichiganInventors: Michael F. Clarke, Sean J. Morrison, Max S. Wicha, Muhammad Al-Hajj
-
Patent number: 8043853Abstract: The present invention relates to compositions and methods employing postnatal (e.g., adult) neural crest stem cells. The stem cells are multipotent and differentiate when transplanted in vivo. Transplantation methods are provided for therapeutic, diagnostic, and research applications.Type: GrantFiled: August 14, 2003Date of Patent: October 25, 2011Assignee: The Regents of the University of MichiganInventors: Sean J. Morrison, Eve Kruger
-
Publication number: 20110092378Abstract: A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise to both more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. We have developed a xenograft model in which we have been able to establish tumors from primary tumors via injection of tumors in the mammary gland of severely immunodeficient mice. These xenograft assay have allowed us to do biological and molecular assays to characterize clonogenic solid tumor stem cells. We have also developed evidence that strongly implicates the Notch pathway, especially Notch 4, as playing a central pathway in carcinogenesis.Type: ApplicationFiled: December 28, 2010Publication date: April 21, 2011Inventors: Michael F. Clarke, Sean J. Morrison, Max S. Wicha, Muhammad Al-Hajj
-
Patent number: 7850961Abstract: A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. We have developed a xenograft model in which we have been able to establish tumors from primary tumors via injection of tumors in the mammary gland of severely immunodeficient mice. These xenograft assay have allowed us to do biological and molecular assays to characterize clonogenic solid tumor stem cells. We have also developed evidence that strongly implicates the Notch pathway, especially Notch 4, as playing a central pathway in carcinogenesis.Type: GrantFiled: September 29, 2006Date of Patent: December 14, 2010Assignee: The Regents of The University of MichiganInventors: Michael F. Clarke, Sean J. Morrison, Max S. Wicha, Muhammad Al-Hajj
-
Patent number: 7713710Abstract: A small percentage of cells within an established tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. The solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. This discovery is the basis for solid tumor stem cell compositions, methods for distinguishing functionally different populations of tumor cells, methods for using these tumor cell populations for studying the effects of therapeutic agents on tumor growth, and methods for identifying and testing novel anti-cancer therapies directed to solid tumor stem cells.Type: GrantFiled: May 24, 2007Date of Patent: May 11, 2010Assignee: The Regents of the University of MichiganInventors: Michael F. Clarke, Sean J. Morrison, Max S. Wicha, Muhammad Al-Hajj
-
Publication number: 20090143418Abstract: The present invention relates to compositions and methods for the preventing, treating, and researching discoloration (e.g., hair graying, hair whitening, undesired change in hair color). In particular, the present invention provides compositions and methods for treating, preventing and researching hair discoloration through inhibition of mTOR function (e.g., mTOR activity, mTOR expression). In addition, the present invention provides methods and compositions that utilize mTOR inhibiting agents in the preventing, treating, and researching hair discoloration.Type: ApplicationFiled: October 31, 2008Publication date: June 4, 2009Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Jesse R. Dixon, Omer H. Yilmaz, Sean J. Morrison
-
Publication number: 20080194022Abstract: A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. We have developed a xenograft model in which we have been able to establish tumors from primary tumors via injection of tumors in the mammary gland of severely immunodeficient mice. These xenograft assay have allowed us to do biological and molecular assays to characterize clonogenic solid tumor stem cells. We have also developed evidence that strongly implicates the Notch pathway, especially Notch 4, as playing a central pathway in carcinogenesis.Type: ApplicationFiled: April 20, 2007Publication date: August 14, 2008Inventors: Michael F. Clarke, Sean J. Morrison, Max S. Wicha, Muhammad Al-Hajj
-
Patent number: 7115360Abstract: A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell.Type: GrantFiled: August 2, 2001Date of Patent: October 3, 2006Assignee: Regents of the University of MichiganInventors: Michael F. Clarke, Sean J. Morrison, Max S. Wicha, Muhammad al-Hajj
-
Patent number: 6984522Abstract: A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. The solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. This discovery is the basis for solid tumor stem cell compositions, methods for distinguishing functionally different populations of tumor cells, methods for using these tumor cell populations for studying the effects of therapeutic agents on tumor growth, and methods for identifying and testing novel anti-cancer therapies directed to solid tumor stem cells.Type: GrantFiled: August 1, 2001Date of Patent: January 10, 2006Assignee: Regents of the University of MichiganInventors: Michael F. Clarke, Sean J. Morrison, Max S. Wicha, Muhammad Al-Hajj
-
Patent number: 6759242Abstract: The present invention relates to the growth of cells in culture under conditions that promote differentiation, cell survival, and/or cellular proliferation. More particularly, culturing neural crest stem cells in low oxygen conditions is described.Type: GrantFiled: October 22, 1999Date of Patent: July 6, 2004Assignee: California Institute of TechnologyInventors: Marie Csete, Sean J. Morrison, Barbara Wold, David J. Anderson
-
Publication number: 20040110288Abstract: The present invention relates to compositions and methods employing postnatal (e.g., adult) neural crest stem cells. The stem cells are multipotent and differentiate when transplanted in vivo. Transplantation methods are provided for therapeutic, diagnostic, and research applications.Type: ApplicationFiled: August 14, 2003Publication date: June 10, 2004Applicant: The Regents of the University of MichiganInventors: Sean J. Morrison, Eve Kruger
-
Publication number: 20040037815Abstract: A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. We have developed a xenograft model in which we have been able to establish tumors from primary tumors via injection of tumors in the mammary gland of severely immunodeficient mice. These xenograft assay have allowed us to do biological and molecular assays to characterize clonogenic solid tumor stem cells. We have also developed evidence that strongly implicates the Notch pathway, especially Notch 4, as playing a central pathway in carcinogenesis.Type: ApplicationFiled: August 25, 2003Publication date: February 26, 2004Inventors: Michael F. Clarke, Sean J. Morrison, Max S. Wicha, Muhammad Al-Hajj
-
Publication number: 20020119565Abstract: A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. This discovery is the basis for solid tumor stem cell compositions, methods for distinguishing functionally different populations of tumor cells, methods for using these tumor cell populations for studying the effects of therapeutic agents on tumor growth, and methods for identifying and testing novel anti-cancer therapies directed to solid tumor stem cells.Type: ApplicationFiled: August 1, 2001Publication date: August 29, 2002Applicant: Regents of the University of MichiganInventors: Michael F. Clarke, Sean J. Morrison, Max S. Wicha, Muhammad Al-Hajj